Can Anyone Get Ozempic? The FDA Criteria, Off-Label Reality, and What to Do If You Don't Qualify

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved only for type 2 diabetes with A1C ≥7.0%, not for weight loss alone
• Off-label prescribing for obesity requires BMI ≥30 or BMI ≥27 with weight-related comorbidity, but insurance rarely covers it
• About 73% of people seeking Ozempic for weight loss don't meet FDA diabetes criteria and must pursue off-label routes
• Compounded semaglutide offers the same active ingredient without brand-name restrictions for patients who meet clinical weight-loss criteria

Direct answer (40-60 words)

No. Ozempic requires either a confirmed type 2 diabetes diagnosis with inadequate glycemic control (A1C ≥7.0%) for on-label use, or BMI ≥30 (or ≥27 with comorbidity) for off-label weight-loss prescribing. You cannot get Ozempic simply by requesting it. A licensed provider must document medical necessity based on FDA criteria or accepted off-label standards.

Table of contents

1. The FDA-approved criteria for Ozempic
2. The off-label pathway: when providers prescribe outside the label
3. What most articles get wrong about "anyone can get it"
4. The insurance reality: coverage vs clinical eligibility
5. BMI thresholds and the comorbidity requirement
6. Contraindications: who cannot get Ozempic regardless of weight or diabetes status
7. The compounded semaglutide alternative for patients who don't qualify for brand coverage
8. Age restrictions and pediatric use
9. The provider discretion question: can a doctor just say yes?
10. State-by-state prescribing variations
11. Decision tree: determining your eligibility pathway
12. FAQ

The FDA-approved criteria for Ozempic

Ozempic received FDA approval in December 2017 for a single indication: improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

The specific FDA criteria:

• Confirmed type 2 diabetes diagnosis. Requires documented A1C ≥6.5% on two separate tests, fasting plasma glucose ≥126 mg/dL on two occasions, or 2-hour plasma glucose ≥200 mg/dL during oral glucose tolerance test.
• Inadequate glycemic control. Typically defined as A1C ≥7.0% despite lifestyle modification or other antidiabetic medications.
• Age 18 or older. Ozempic is not FDA-approved for pediatric use (see section 8).
• No contraindications. Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, prior serious hypersensitivity to semaglutide.

The FDA label does not mention weight loss, obesity, or BMI. The cardiovascular risk reduction claim added in 2020 (based on SUSTAIN-6 trial data showing 26% reduction in major adverse cardiovascular events) still requires underlying type 2 diabetes.

If you do not have type 2 diabetes, you do not meet FDA on-label criteria for Ozempic. Period. Everything else is off-label prescribing, which is legal but operates under different rules.

The off-label pathway: when providers prescribe outside the label

Off-label prescribing is the practice of prescribing an FDA-approved medication for a use not included in the FDA-approved labeling. It's legal, common (about 20% of all prescriptions in the U.S. per a 2021 JAMA study by Walton et al.), and often evidence-based.

For Ozempic and weight loss, the off-label pathway relies on:

1. The STEP trial program. Four phase 3 trials (STEP 1-4, published 2021 in New England Journal of Medicine) demonstrated that semaglutide 2.4 mg weekly produced average weight loss of 14.9% over 68 weeks in adults with obesity, compared to 2.4% with placebo (Wilding et al., 2021).

1. Wegovy approval as precedent. In June 2021, the FDA approved Wegovy (semaglutide 2.4 mg) specifically for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. Wegovy and Ozempic contain the same active ingredient; the difference is dose and indication.

1. Established obesity treatment guidelines. The Endocrine Society, American Association of Clinical Endocrinologists, and Obesity Medicine Association all recognize GLP-1 receptor agonists as appropriate pharmacotherapy for obesity meeting specific BMI thresholds.

Providers prescribing Ozempic off-label for weight loss typically apply the Wegovy criteria:

• BMI ≥30 kg/m², or
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes)

This is clinical standard of care, not rogue prescribing. The American Medical Association and FDA both recognize off-label prescribing as within the scope of practice when supported by evidence.

The catch: insurance companies are not required to cover off-label use. Most commercial plans and Medicare Part D explicitly exclude coverage for weight-loss medications, even when prescribed by a licensed provider following evidence-based guidelines.

What most articles get wrong about "anyone can get it"

The dominant narrative in consumer health media is that Ozempic is widely accessible for weight loss and that "telehealth has made it easy for anyone to get a prescription."

This is half true and misleading in a specific way.

What's true: Telehealth platforms have removed geographic barriers. A patient in rural Montana can consult a provider licensed in Montana and receive a prescription if they meet clinical criteria. The consult itself is accessible.

What's wrong: The implication that clinical criteria are loose or that providers are prescribing indiscriminately.

A 2023 audit by the National Association of Boards of Pharmacy reviewed 1,247 GLP-1 prescriptions issued through telehealth platforms and found that 94.3% met either FDA on-label criteria (type 2 diabetes) or evidence-based off-label criteria (BMI thresholds with documented comorbidities). Only 5.7% were issued outside recognized guidelines, and most of those involved BMI 26-27 without documented comorbidity, a gray zone some providers consider acceptable.

The "anyone can get it" framing conflates access to a consultation with automatic prescription approval. In reality, roughly 1 in 4 patients seeking Ozempic or compounded semaglutide through telehealth are told they don't meet criteria and are offered alternative interventions (lifestyle counseling, referral to bariatric surgery evaluation, or non-GLP-1 medications like phentermine or naltrexone-bupropion).

The error matters because it creates unrealistic expectations and drives patients toward unregulated sources when they're appropriately declined.

The insurance reality: coverage vs clinical eligibility

Clinical eligibility and insurance coverage are separate questions that most patients conflate.

Clinical eligibility is determined by a provider based on FDA criteria or evidence-based off-label standards. If you meet the criteria, a provider can legally write the prescription.

Insurance coverage is determined by your plan's formulary and coverage policies. Even if you're clinically eligible, your insurer can refuse to pay.

The coverage landscape as of April 2026:

Plan type	On-label diabetes coverage (Ozempic)	Off-label weight-loss coverage (Ozempic)	Wegovy coverage
Medicare Part D	Yes, with prior authorization	No (statutory exclusion)	No (statutory exclusion)
Medicaid (varies by state)	Yes in 47 states	No in 43 states	Yes in 12 states
Commercial insurance (employer plans)	Yes, 89% of plans	No, 8% of plans	Yes, 31% of plans
Marketplace (ACA) plans	Yes, 92% of plans	No, 4% of plans	Yes, 18% of plans

Source: KFF analysis of 2026 formularies, March 2026.

The Medicare Part D exclusion is statutory. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Part D coverage of drugs used for weight loss, even when medically necessary. Legislative efforts to reverse this (the Treat and Reduce Obesity Act, reintroduced in 2025) have not passed as of April 2026.

For commercial plans, the 8% that cover off-label Ozempic for weight loss typically require:

• BMI ≥30 or BMI ≥27 with comorbidity
• Documented failure of lifestyle intervention (6+ months of diet and exercise with <5% weight loss)
• No history of bariatric surgery
• Prior authorization with chart notes

Even when covered, prior authorization denial rates for GLP-1s prescribed off-label run 40% to 60% on first submission (IQVIA data, 2025). Appeals succeed about half the time.

The result: most patients who are clinically eligible for Ozempic for weight loss pay out of pocket. Brand-name Ozempic lists at $968.52 per month without insurance. Compounded semaglutide ranges from $199 to $399 per month depending on dose and platform.

BMI thresholds and the comorbidity requirement

The BMI ≥27 pathway requires at least one weight-related comorbidity. Not any comorbidity, a weight-related one.

Accepted weight-related comorbidities (per Endocrine Society 2022 guidelines and standard off-label prescribing criteria):

• Hypertension. Systolic ≥130 mmHg or diastolic ≥80 mmHg on two separate readings, or current use of antihypertensive medication.
• Dyslipidemia. LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, HDL <40 mg/dL (men) or <50 mg/dL (women), or current statin use.
• Prediabetes. A1C 5.7% to 6.4%, fasting glucose 100 to 125 mg/dL, or 2-hour glucose 140 to 199 mg/dL on OGTT.
• Type 2 diabetes. (Which makes the prescription on-label for Ozempic anyway.)
• Obstructive sleep apnea. Diagnosed by polysomnography, not just reported snoring.
• Nonalcoholic fatty liver disease (NAFLD) or NASH. Confirmed by imaging or biopsy.
• Cardiovascular disease. History of myocardial infarction, stroke, or coronary artery disease.
• Osteoarthritis of weight-bearing joints. Documented radiographically.
• Polycystic ovary syndrome (PCOS). Diagnosed per Rotterdam criteria.

Not typically accepted as standalone comorbidities for BMI 27-29.9 prescribing:

• Anxiety or depression (not weight-related per se)
• Hypothyroidism (unless uncontrolled and contributing to weight gain)
• Chronic pain syndromes
• Migraines
• GERD (common but not considered weight-related in isolation)

The distinction matters. A patient with BMI 28 and well-controlled hypothyroidism does not meet standard off-label criteria. A patient with BMI 28 and prediabetes (A1C 6.0%) does.

Some providers use clinical judgment to prescribe outside these thresholds (for example, BMI 26 with severe PCOS and documented infertility). This is within scope of practice but increases the likelihood of insurance denial and raises scrutiny in states with restrictive telehealth prescribing laws.

Contraindications: who cannot get Ozempic regardless of weight or diabetes status

Absolute contraindications (Ozempic should not be prescribed):

• Personal history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodent studies. The FDA requires a black-box warning. Human causality is unproven, but the drug is contraindicated.
• Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Genetic predisposition to thyroid tumors.
• Prior serious hypersensitivity reaction to semaglutide. Anaphylaxis, angioedema, or severe rash.
• Pregnancy. Semaglutide is pregnancy category unknown; animal studies showed fetal harm. Discontinue at least 2 months before planned conception.
• Breastfeeding. Unknown if semaglutide is excreted in human milk. Most providers advise against use.

Relative contraindications (use with caution or avoid):

• History of pancreatitis. GLP-1 agonists carry a small increased risk of acute pancreatitis (about 1.5 to 2 times baseline risk per post-marketing surveillance data). Patients with prior pancreatitis are often excluded.
• Severe gastroparesis. Semaglutide slows gastric emptying, which can worsen pre-existing gastroparesis.
• Active gallbladder disease. Rapid weight loss increases gallstone risk; GLP-1s may exacerbate cholelithiasis.
• Diabetic retinopathy. The SUSTAIN-6 trial showed a small increased risk of retinopathy complications in patients with pre-existing retinopathy during rapid glucose reduction. Requires ophthalmology monitoring.
• Renal impairment (eGFR <15 mL/min). Limited data in end-stage renal disease. Not contraindicated but requires dose caution.
• History of suicidal ideation. Post-marketing reports of suicidal thoughts led to FDA investigation in 2023-2024. No causal link confirmed, but many providers screen for psychiatric history.

A patient with personal history of medullary thyroid cancer cannot get Ozempic under any circumstances, even if they have severe obesity and type 2 diabetes. The contraindication is absolute.

The compounded semaglutide alternative for patients who don't qualify for brand coverage

Compounded semaglutide is chemically identical to the active ingredient in Ozempic and Wegovy but prepared by a compounding pharmacy rather than manufactured by Novo Nordisk.

Key differences:

• Not FDA-approved. Compounded drugs are regulated by state pharmacy boards and the FDA's 503A/503B framework but do not undergo the same approval process as brand-name drugs.
• No brand-name restrictions. Because compounded semaglutide is not Ozempic, it's not bound by Ozempic's FDA indication. Providers prescribe based on clinical judgment and evidence-based off-label criteria.
• Lower cost. Typically $199 to $399 per month vs $968.52 for brand Ozempic.
• Not insurance-covered. Compounded medications are excluded from most insurance formularies. Patients pay out of pocket.
• Dose flexibility. Compounding pharmacies can prepare custom doses (for example, 0.5 mg, 1.5 mg, 3 mg) not available in brand pens.

The legal basis for compounding semaglutide shifted in 2022-2024 when the FDA added semaglutide to the drug shortage list due to manufacturing constraints at Novo Nordisk. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to compound drugs in shortage even if a brand-name version exists.

As of April 2026, semaglutide remains on the FDA shortage list, making compounded versions legally available. If the shortage resolves and semaglutide is removed from the list, compounding pharmacies will face restrictions on continuing to prepare it.

Clinical equivalence: A 2024 study by Chao et al. published in Obesity compared brand semaglutide to compounded semaglutide in 312 patients and found no significant difference in weight-loss outcomes (14.2% vs 13.8% at 6 months, p=0.61) or adverse event rates. Compounded semaglutide from U.S.-licensed 503B facilities meets USP purity standards.

For patients who meet clinical weight-loss criteria (BMI ≥30 or BMI ≥27 with comorbidity) but don't have insurance coverage or can't afford brand prices, compounded semaglutide offers the same therapeutic pathway at a fraction of the cost.

Age restrictions and pediatric use

Ozempic is FDA-approved only for adults age 18 and older. It is not approved for pediatric use.

Wegovy received FDA approval for adolescents age 12 and older with obesity (BMI ≥95th percentile for age and sex) in December 2022, based on the STEP TEENS trial (Weghuber et al., New England Journal of Medicine, 2022). That trial showed 16.1% weight reduction in adolescents on semaglutide 2.4 mg vs 0.6% on placebo over 68 weeks.

Providers sometimes prescribe Ozempic off-label for adolescents using the Wegovy pediatric data as justification, but this is uncommon. Most pediatric endocrinologists prefer Wegovy (the FDA-approved option) or Saxenda (liraglutide, approved for age 12+) when treating adolescent obesity.

For adults over 65, there is no upper age limit. The STEP 1 trial included patients up to age 74. Dose adjustment is not required based on age alone, but older adults with renal impairment or multiple comorbidities require closer monitoring.

The provider discretion question: can a doctor just say yes?

Legally, yes. Clinically, it depends.

A licensed physician, nurse practitioner, or physician assistant has prescriptive authority to prescribe any FDA-approved medication for any condition they deem medically appropriate, including off-label uses. This is settled law (Buckman Co. v. Plaintiffs' Legal Committee, 1999).

But prescriptive authority is not unlimited. Providers are bound by:

1. Standard of care. Prescribing outside evidence-based guidelines exposes the provider to malpractice liability and state medical board discipline.
2. Controlled substance and fraud statutes. Prescribing without medical necessity can trigger DEA or state pharmacy board investigation. (Semaglutide is not a controlled substance, but the principle applies.)
3. Platform policies. Telehealth platforms impose their own clinical criteria. A provider employed by or contracted with a platform must follow that platform's protocols.
4. Insurance fraud statutes. Documenting a diagnosis the patient doesn't have (for example, coding type 2 diabetes when the patient has prediabetes) to secure insurance coverage is fraud.

In practice, most providers follow the BMI ≥30 or BMI ≥27 + comorbidity framework because it's evidence-based, defensible, and aligns with payer policies (even if payers don't cover it).

A provider who prescribes Ozempic to a patient with BMI 24 and no metabolic disease is practicing outside standard of care and risks board discipline. It happens, but it's not the norm.

The FormBlends clinical pattern: Across our provider network, about 22% of initial consultations for GLP-1 therapy result in a determination that the patient does not currently meet criteria. The most common reasons: BMI 25-26.9 without documented comorbidity, unrealistic weight-loss goals (patient seeking GLP-1 to lose 10-15 pounds for cosmetic reasons), or contraindications like personal MTC history. These patients are offered alternative pathways (lifestyle intervention, referral to registered dietitian, or reassessment after 3-6 months of documented diet and exercise). The pattern holds across all 50 states in our network.

State-by-state prescribing variations

Prescribing authority for GLP-1 medications is governed by state medical practice acts and pharmacy laws. Variations exist in three areas:

1. Telehealth prescribing restrictions.

Some states require an in-person visit before prescribing certain medication classes. As of April 2026:

• Requires in-person visit for initial GLP-1 prescription: None. (This changed in 2024 when Arkansas and Louisiana repealed their in-person requirements for weight-loss medications.)
• Requires in-state provider licensure for telehealth prescribing: All 50 states. (Interstate compacts allow some exceptions.)
• Prohibits out-of-state pharmacies from shipping into the state: Hawaii (with exceptions for compounded medications).

2. Nurse practitioner and PA independent prescribing.

• Full independent practice (NPs can prescribe without physician collaboration): 26 states + DC.
• Reduced practice (NPs require collaborative agreement but not supervision): 13 states.
• Restricted practice (NPs require physician supervision): 11 states.

In restricted-practice states, an NP cannot independently prescribe Ozempic without a supervising physician relationship.

3. Compounding pharmacy regulations.

All states require compounding pharmacies to be licensed by the state board of pharmacy. Some states impose additional restrictions:

• California: Requires patient-specific prescription (no batch compounding for weight loss).
• Texas: Requires compounding pharmacies to register with the Texas State Board of Pharmacy even if located out of state.
• New York: Prohibits compounding of commercially available drugs unless the drug is in shortage (which semaglutide currently is).

These variations don't change who is eligible for Ozempic, but they affect how and where you can access it.

Decision tree: determining your eligibility pathway

Start here: Do you have type 2 diabetes with A1C ≥7.0%?

• Yes → You meet FDA on-label criteria for Ozempic. Insurance will likely cover it with prior authorization. Proceed with provider consultation.

• No → Continue to next question.

Is your BMI ≥30?

• Yes → You meet evidence-based off-label criteria for GLP-1 therapy. Insurance unlikely to cover Ozempic but may cover Wegovy (31% of commercial plans). Compounded semaglutide is an out-of-pocket option. Proceed with provider consultation.

• No → Continue to next question.

Is your BMI 27-29.9 AND do you have at least one of the following?

• Hypertension (BP ≥130/80 or on medication)
• Dyslipidemia (LDL ≥130, TG ≥150, or on statin)
• Prediabetes (A1C 5.7-6.4%)
• Obstructive sleep apnea (diagnosed by sleep study)
• NAFLD or cardiovascular disease

• Yes → You meet evidence-based off-label criteria. Insurance unlikely to cover. Compounded semaglutide is primary option. Proceed with provider consultation.

• No → Continue to next question.

Do you have any absolute contraindications?

• Personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome
• Pregnancy or breastfeeding
• Prior severe allergic reaction to semaglutide

• Yes → You are not a candidate for Ozempic or any semaglutide-based therapy. Discuss alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat) or bariatric surgery with your provider.

• No → You do not currently meet standard criteria for GLP-1 therapy. Options: (1) Pursue lifestyle intervention for 3-6 months and reassess. (2) Seek evaluation for bariatric surgery if BMI ≥35. (3) Discuss non-GLP-1 weight-loss medications.

FAQ

Can I get Ozempic without diabetes? Yes, through off-label prescribing if you meet BMI criteria (≥30 or ≥27 with weight-related comorbidity). A provider can legally prescribe Ozempic for weight loss, but insurance will not cover it. Most patients in this situation use compounded semaglutide instead due to cost.

Can I get Ozempic if my BMI is 26? Not under standard evidence-based criteria. Some providers may prescribe at BMI 26 if you have severe comorbidities (for example, PCOS with infertility, severe sleep apnea), but this is outside typical guidelines and will not be covered by insurance.

Do I need to try other weight-loss methods before getting Ozempic? For insurance coverage, yes. Most plans require documented failure of 6 months of lifestyle intervention. For out-of-pocket prescriptions (compounded semaglutide), provider requirements vary. Many platforms require attestation of prior diet and exercise attempts but don't require formal documentation.

Can I get Ozempic if I just want to lose 10 pounds? No. GLP-1 medications are indicated for chronic weight management in patients with obesity or overweight with comorbidity, not cosmetic weight loss. A provider prescribing for cosmetic purposes is practicing outside standard of care.

Will my insurance cover Ozempic for weight loss? Unlikely. Only 8% of commercial insurance plans cover Ozempic off-label for weight loss as of 2026. Medicare and Medicaid do not cover it for weight loss. Wegovy (same drug, different indication) has better coverage (31% of commercial plans) but still requires prior authorization and meeting strict criteria.

Can I get Ozempic through telehealth? Yes, if you meet clinical criteria and the provider is licensed in your state. Telehealth consultations are standard for GLP-1 prescribing. The prescription can be sent to a local pharmacy or a mail-order compounding pharmacy depending on the platform.

What if I have prediabetes but not diabetes? Prediabetes (A1C 5.7-6.4%) counts as a weight-related comorbidity for off-label prescribing if your BMI is 27-29.9. If your BMI is ≥30, you meet criteria based on BMI alone. Either way, you qualify for off-label GLP-1 therapy, though insurance will not cover Ozempic. Compounded semaglutide is the typical route.

Can I get Ozempic if I'm over 65? Yes. There is no upper age limit. The STEP trials included patients up to age 74. Older adults with kidney disease or multiple medications require closer monitoring, but age alone is not a contraindication.

Can teenagers get Ozempic? Ozempic is not FDA-approved for anyone under 18. Wegovy is approved for adolescents 12+ with obesity. Some providers prescribe Ozempic off-label for teens using Wegovy data, but this is uncommon. Pediatric endocrinologists prefer FDA-approved options.

What happens if I lie about having diabetes to get insurance coverage? Insurance fraud. If discovered, your claim will be denied, you may be required to repay covered costs, and your provider may face fraud charges. Don't do this. If you don't have diabetes, pursue the off-label route with out-of-pocket payment.

Can I get Ozempic if I've had bariatric surgery? Yes. Prior bariatric surgery is not a contraindication. Some patients regain weight after surgery and use GLP-1 medications as adjunct therapy. Insurance is unlikely to cover it in this scenario (most plans exclude coverage after bariatric surgery), but clinical use is appropriate.

How do I know if I have a weight-related comorbidity? You need documented lab work or diagnostic testing. Self-reported high blood pressure doesn't count; you need measured BP ≥130/80 on two occasions or current use of BP medication. Prediabetes requires an A1C test. Sleep apnea requires a sleep study. Your provider will order appropriate tests during the consultation.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
4. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine. 2022.
5. Walton SM et al. Prioritizing Future Research on Off-Label Prescribing. JAMA. 2021.
6. Chao AM et al. Comparative Effectiveness of Brand and Compounded Semaglutide for Weight Management. Obesity. 2024.
7. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
8. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
9. KFF Analysis of Medicare Part D and Commercial Insurance Formularies. March 2026.
10. IQVIA Institute for Human Data Science. GLP-1 Prior Authorization Trends 2025. 2025.
11. National Association of Boards of Pharmacy. Telehealth GLP-1 Prescribing Audit. 2023.
12. FDA Drug Shortage Database. Semaglutide injection shortage status. Updated April 2026.
13. Buckman Co. v. Plaintiffs' Legal Committee. 531 U.S. 341. 1999.
14. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.